| scholarly article | Q13442814 |
| P2093 | author name string | Sam Hopkins | |
| Philippe A Gallay | |||
| Udayan Chatterji | |||
| Barrie Wilkinson | |||
| Matthew A Gregory | |||
| Jose A Garcia-Rivera | |||
| Michael Bobardt | |||
| Kai Lin | |||
| P2860 | cites work | Epidemiology of hepatitis C virus infection | Q22305500 |
| New direct-acting antivirals in the development for hepatitis C virus infection | Q37823323 | ||
| New hepatitis C therapies in clinical development | Q37911056 | ||
| Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors. | Q37940114 | ||
| Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents | Q37968485 | ||
| Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity | Q38292825 | ||
| The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection | Q39378324 | ||
| A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility | Q39394432 | ||
| Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family | Q39579921 | ||
| Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors | Q39736462 | ||
| Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor | Q39816111 | ||
| Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. | Q40113778 | ||
| Mobility analysis of an NS5A-GFP fusion protein in cells actively replicating hepatitis C virus subgenomic RNA. | Q40179334 | ||
| Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins | Q40376973 | ||
| Specific inhibition of hepatitis C virus replication by cyclosporin A. | Q40607971 | ||
| Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes | Q40622941 | ||
| HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors | Q40998392 | ||
| New antiviral agents for hepatitis C | Q42105512 | ||
| Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner | Q42780244 | ||
| Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group | Q42984733 | ||
| The domain 2 of the HCV NS5A protein is intrinsically unstructured | Q42996890 | ||
| Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. | Q42999156 | ||
| The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. | Q43046668 | ||
| Emerging drugs for hepatitis C | Q57271196 | ||
| Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy | Q83263799 | ||
| Multiple cyclophilins involved in different cellular pathways mediate HCV replication | Q24319590 | ||
| Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus | Q24323301 | ||
| Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment | Q24337128 | ||
| Stimulation of hepatitis C virus (HCV) nonstructural protein 3 (NS3) helicase activity by the NS3 protease domain and by HCV RNA-dependent RNA polymerase | Q27470016 | ||
| Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase | Q27473147 | ||
| Diverse Effects of Cyclosporine on Hepatitis C Virus Strain Replication | Q27473218 | ||
| NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon | Q27477455 | ||
| Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In Vitro | Q27480361 | ||
| Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl cis/trans Isomerase Activity of Cyclophilins A and B | Q27488369 | ||
| Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex | Q27488788 | ||
| Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics | Q27489037 | ||
| The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication | Q27489053 | ||
| SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro | Q27490844 | ||
| Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A | Q27491303 | ||
| Global epidemiology of hepatitis C virus infection | Q27860799 | ||
| Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes | Q27861119 | ||
| DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A | Q28748683 | ||
| NPS@: network protein sequence analysis | Q29616421 | ||
| Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium | Q29619747 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Cyclophilin inhibitors for the treatment of HCV infection. | Q30318599 | ||
| Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes | Q33204253 | ||
| The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A. | Q33529510 | ||
| A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach | Q33707739 | ||
| Hepatitis C virus NS5A: tales of a promiscuous protein | Q33980571 | ||
| Epidemiology of hepatitis C virus (HCV) infection | Q33995067 | ||
| Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures. | Q34185327 | ||
| The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro | Q34504825 | ||
| American Gastroenterological Association technical review on the management of hepatitis C. | Q36364156 | ||
| Treating viral hepatitis C: efficacy, side effects, and complications | Q36564615 | ||
| Current and future management of chronic hepatitis C infection | Q37143005 | ||
| Development of novel antiviral therapies for hepatitis C virus | Q37801585 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 5113-5121 | |
| P577 | publication date | 2012-07-16 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir | |
| P478 | volume | 56 |
| Q42196934 | A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response |
| Q39191241 | Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model |
| Q38990715 | Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection |
| Q38260235 | Antiviral drug discovery: broad-spectrum drugs from nature |
| Q26771251 | Chaperones in hepatitis C virus infection |
| Q28551538 | Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175 |
| Q27468931 | Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection |
| Q35385005 | Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories |
| Q38064282 | Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection |
| Q59356755 | Cyclophilins and cyclophilin inhibitors in nidovirus replication |
| Q59352119 | Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of HBV Infection |
| Q34332546 | Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance |
| Q26779128 | Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection |
| Q28364857 | Infection Counter: Automated Quantification of in Vitro Virus Replication by Fluorescence Microscopy |
| Q42246268 | Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients |
| Q34261735 | Novel indole-2-carboxamide compounds are potent broad-spectrum antivirals active against western equine encephalitis virus in vivo. |
| Q37144087 | Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility |
| Q34329744 | Profile of alisporivir and its potential in the treatment of hepatitis C. |
| Q33424900 | Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). |
| Q35742761 | The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action |
| Q33797891 | The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance |
| Q38274889 | The role of immunophilins in viral infection |
| Q28652236 | Virus-host interactomics: new insights and opportunities for antiviral drug discovery |
Search more.